Fernando and Fletcher [94] evidenced that antibodies targeting TEM8 reduce tumor volume approximately of 53% and confirmed a tumor growth delay of 49% in the xenograft model of colorectal carcinoma compared to control mice. This evidence concerns the gene ANTXR1 and colorectal carcinoma.